Cargando…
Belatacept in kidney transplant patients with systemic lupus erythematosus
OBJECTIVES: Lupus nephritis (LN) requires renal replacement therapy in 10%–30% of patients. About 30% of these patients receive a kidney transplant. Belatacept is a second-generation, selective, T-cell co-stimulator blocker (inhibits cytotoxic, T-lymphocyte antigen 4, CTLA-4) used as an alternative...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6928461/ https://www.ncbi.nlm.nih.gov/pubmed/31908816 http://dx.doi.org/10.1136/lupus-2019-000355 |